N-Deshydroxyethyl dasatinib
CAS: 910297-51-7
Rif. 3D-FD21202
| 1mg | Fuori produzione | ||
| 2mg | Fuori produzione | ||
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione |
Informazioni sul prodotto
- N-(2-Chloro-6-methylphenyl)-2-[[2-methyl-6-(1-piperazinyl)-4-pyrimidinyl]amino]-5-thiazolecarboxamideDasatinib metabolite M4
Dasatinib is a multi-kinase inhibitor that is used in the treatment of acute lymphoblastic leukemia. It is metabolized by the cytochrome P450 enzyme CYP3A4, which may lead to an increase in the plasma concentrations of dasatinib when it is coadministered with CYP3A4 substrates such as rifampicin or phenytoin. Dasatinib also undergoes glucuronidation and sulfation, which are metabolic pathways that may contribute to its elimination from the body. The pharmacokinetic properties of dasatinib have been studied in healthy volunteers and patients with acute lymphoblastic leukemia. These studies showed that dasatinib has a half-life of about 12 hours and a clearance rate between 0.076 - 0.105 L/h/kg. The pharmacokinetic study also found that dasatinib levels were higher in patients who had received chemotherapy than those who had not before administration of
